| DBV TECHNOLOGIES ADR |
| USA |
| Gesundheit |
| US23306J3095 / A40WEX |
| DBV1 (Frankfurt) / DBVT (NASDAQ) |
| FRA:DBV1, ETR:DBV1, DBV1:GR, NASDAQ:DBVT |
| - |
| https://dbv-technologies... |
|
DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, specializing in immunotherapy treatments for food allergies. The company is known for developing the Viaskin patch, a proprietary transdermal technology ..
>Volltext.. |
| 999.78 Mio. EUR |
| 852.07 Mio. EUR |
| - |
| -115.97 Mio. EUR |
| -126.18 Mio. EUR |
| -4.52 EUR |
| 18.57 Mio. EUR |
| 166.28 Mio. EUR |
| -104.1 Mio. EUR |
| 3.35 |
| - |
| -29.54% |
| - |
| - |
| - |
| - |
| DBV TECHNOLOGIES ADR, DBV TECHNOLOGIES, DBV TECH |
| 08.04.26 |
|